Shots:

• Pfizer to receive Axsome’s common shares of ~$8M- $3M in cash as upfront- ~$323M regulatory & commercial milestones and royalties in sales of the therapies and has right of first negotiation on any potential strategic transactions involving AXS-12 and AXS-14
• Axsome to receive an exclusive license to Pfizer’s clinical- nonclinical data and intellectual property for AXS-12 (reboxetine) and an exclusive right to develop & commercialize AXS-14 (esreboxetine) in the US
• AXS-12 is a highly selective and potent norepinephrine reuptake inhibitor- being evaluated in P-II study for narcolepsy with anticipated initiation of P-III study in 2020 while AXS-14 is SS-enantiomer of reboxetine which met its 1EPs in P-III & P-II study for the treatment of fibromyalgia

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Axsome